Infectious disease
In a weekend interview on CBS’ “Face the Nation,” Albert Bourla, chief executive officer of Pfizer indicated they may have key data from its Phase III trial of the vaccine to the U.S. Food and Drug Administration by the end of October.
AstraZeneca resumed its vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
It was a busy week for clinical trial updates. Here’s a look.
Six months into a global pandemic and public trust is waning in its support for public health officials in charge of the nation’s response to the novel coronavirus, according to a new poll.
Despite a temporary pause on its COVID-19 vaccine trial, AstraZeneca Chief Executive Officer Pascal Soriot said the preventative drug could still be available for commercial use by the end of the year, or in early 2021 barring any other setback.
Understanding immunology can be challenging, especially in the midst of a global pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.
In July, the study was paused after another patient experienced neurological issues.
Preclinical data for Pfizer and BioNTech’s Phase II/III COVID-19 mRNA vaccine candidate generated BNT162b2 strong anti-viral effects against an infectious SARS-CoV-2 challenge.
PRESS RELEASES